NCT07819695
Safety and Tolerability Evaluation of BP-LT
At risk: Primary endpoint(s) modified.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Recruitment opened
- Start date changed from estimate of Nov 1, 2026 to Nov 3, 2026
- Site details revised
- Notable Primary endpoint(s) modified
- Study title shortened, about 3 words
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Incidence of Serious Adverse Events (SAEs) and Suspected Unexpected Serious Adverse Reactions (SUSARs) per arm, by product causality.
Timeframe: From baseline (Day 0) to Day 7
Arms and interventions
BP-LTExperimental
Received test product containing BP-LT
PlaceboPlacebo comparator
Received placebo product without BP-LT
Dietary supplements: BP-LT, Placebo
Sites
1 site in 1 country
- The International Centre for Diarrheal Disease Management in Bangladesh (icddr,b)Dhaka, Bangladesh